DeepSeek's AI development is reshaping China's venture capital landscape following a three-year decline, as investments in China-based companies decreased to $48.86 billion in 2024, according to Pitchbook data. Insilico Medicine has successfully secured $110 million in series E investments, confirmed by CEO Alex Zhavoronkov, who emphasized the increasing international interest in Chinese AI companies. Beijing is demonstrating support for the tech sector, as Zheng Shanjie announced a new fund to raise 1 trillion yuan for tech investments. Investors are advised to acknowledge the risks in China, as emphasized by Xuhui Shao, who highlighted potential obstacles like capital flow restrictions.